Let's Know! Intervention for Childhood Language Disorders
(LK!2 Trial)
Trial Summary
What is the purpose of this trial?
In the proposed project, the investigators will conduct a multisite randomized controlled trial (RCT) to determine the efficacy of Let's Know!2, a small-group, language focused comprehension intervention, on children's lower- and higher-level language skills and comprehension skills in the short- and long-term (Specific Aims 1 and 2). The investigators will also explore whether intervention effects are moderated by dosage, initial language skill, developmental language disorder (DLD) status, word reading skill, nonverbal IQ, and family socioeconomic status (Specific Aim 3). Children who have low language skills and are thus at risk for reading comprehension difficulties will participate in the study. Children will be randomly assigned to receive Let's Know! in small groups at their respective schools or to a business-as-usual control condition. The investigators will measure children's language and comprehension skills at the beginning and end of Grade 1 as well as in Grade 2 and Grade 3. The investigators hypothesize that children who experience Let's Know! will end Grade 1 with higher language skills than children in the control condition and that this will translate into better listening and reading comprehension skills as these children matriculate through elementary school.
Research Team
Tiffany P Hogan, PhD
Principal Investigator
MGH Institute of Health Professions
Eligibility Criteria
This trial is for Grade 1 children with low language skills, at risk of comprehension difficulties. They must have parental consent, score below a specific language screener threshold, and possess basic English proficiency. Children with profound disabilities or serious behavior issues affecting classroom participation are excluded.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Let's Know! small-group or TierL 2 Intervention (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
MGH Institute of Health Professions
Lead Sponsor
University of Kansas
Collaborator
Lynne A. Bui
University of Kansas
Chief Medical Officer since 2017
MD from the David Geffen UCLA School of Medicine, BA in Molecular and Cell Biology from University of California, Berkeley
Randy Milby
University of Kansas
Chief Executive Officer since 2017
BS in Pharmacy from The University of Kansas, MBA in Finance/Marketing from Washington University in St. Louis – Olin Business School
Ohio State University
Collaborator
Dr. John J. Warner
Ohio State University
Chief Executive Officer since 2023
MD, MBA
Dr. Peter Mohler
Ohio State University
Chief Medical Officer since 2023
PhD in Molecular Biology
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborator
Joshua M. Levy
National Institute on Deafness and Other Communication Disorders (NIDCD)
Chief Medical Officer
MD, MPH, MS
Debara L. Tucci
National Institute on Deafness and Other Communication Disorders (NIDCD)
Chief Executive Officer since 2019
MD, MS, MBA